These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28507200)

  • 41. Molecular design, synthesis and biological evaluation of cage compound-based inhibitors of hepatitis C virus p7 ion channels.
    Shiryaev VA; Radchenko EV; Palyulin VA; Zefirov NS; Bormotov NI; Serova OA; Shishkina LN; Baimuratov MR; Bormasheva KM; Gruzd YA; Ivleva EA; Leonova MV; Lukashenko AV; Osipov DV; Osyanin VA; Reznikov AN; Shadrikova VA; Sibiryakova AE; Tkachenko IM; Klimochkin YN
    Eur J Med Chem; 2018 Oct; 158():214-235. PubMed ID: 30218908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of Hepatitis C Virus in Mice by a Small Interfering RNA Targeting a Highly Conserved Sequence in Viral IRES Pseudoknot.
    Moon JS; Lee SH; Kim EJ; Cho H; Lee W; Kim GW; Park HJ; Cho SW; Lee C; Oh JW
    PLoS One; 2016; 11(1):e0146710. PubMed ID: 26751678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benzothiazepinecarboxamides: Novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions.
    Kim HY; Kong S; Oh S; Yang J; Jo E; Ko Y; Kim SH; Hwang JY; Song R; Windisch MP
    Antiviral Res; 2016 May; 129():39-46. PubMed ID: 26850830
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A cyclic peptide mimic of an RNA recognition motif of human La protein is a potent inhibitor of hepatitis C virus.
    Manna AK; Kumar A; Ray U; Das S; Basu G; Roy S
    Antiviral Res; 2013 Mar; 97(3):223-6. PubMed ID: 23291201
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C Virus Resistance to Carbohydrate-Binding Agents.
    Izquierdo L; Oliveira C; Fournier C; Descamps V; Morel V; Dubuisson J; Brochot E; Francois C; Castelain S; Duverlie G; Helle F
    PLoS One; 2016; 11(2):e0149064. PubMed ID: 26871442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolomics and proteomics approaches to characterize and assess proteins of bear bile powder for hepatitis C virus.
    Wang XJ; Yan GL; Zhang AH; Sun H; Piao CY; Li WY; Sun C; Wu XH; Li XH; Chen Y
    Chin J Nat Med; 2013 Nov; 11(6):653-65. PubMed ID: 24345507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design and synthesis of novel carbocyclic versions of 2'-spirocyclopropyl ribonucleosides as potent anti-HCV agents.
    Oh CH; Kim E; Hong JH
    Nucleosides Nucleotides Nucleic Acids; 2011 Jun; 30(6):423-39. PubMed ID: 21780908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization.
    Ying H; Ji X; Hart ML; Gupta K; Saifuddin M; Zariffard MR; Spear GT
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):327-35. PubMed ID: 15117456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
    Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
    Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and antiviral evaluation of 2'-C-methyl analogues of 5-alkynyl- and 6-alkylfurano- and pyrrolo[2,3-d]pyrimidine ribonucleosides.
    Januszczyk P; Fogt J; Boryski J; Izawa K; Onishi T; Neyts J; De Clercq E
    Nucleosides Nucleotides Nucleic Acids; 2009 May; 28(5):713-23. PubMed ID: 20183611
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
    Shakya N; Vedi S; Liang C; Agrawal B; Tyrrell DL; Kumar R
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6475-80. PubMed ID: 22985854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
    Behrendt P; Perin P; Menzel N; Banda D; Pfaender S; Alves MP; Thiel V; Meuleman P; Colpitts CC; Schang LM; Vondran FWR; Anggakusuma ; Manns MP; Steinmann E; Pietschmann T
    Antiviral Res; 2017 Nov; 147():19-28. PubMed ID: 28923507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C Virus Relapse 78 Weeks After Completion of Successful Direct-Acting Therapy.
    Boschi C; Colson P; Tissot-Dupont H; Bernit E; Botta-Fridlund D; Aherfi S
    Clin Infect Dis; 2017 Sep; 65(6):1051-1053. PubMed ID: 28510632
    [No Abstract]   [Full Text] [Related]  

  • 55. Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    Samji H; Yu A; Kuo M; Alavi M; Woods R; Alvarez M; Dore GJ; Tyndall M; Krajden M; Janjua NZ;
    J Hepatol; 2017 Nov; 67(5):909-917. PubMed ID: 28684103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
    Zhen L; Dai L; Wen X; Yao L; Jin X; Yang XW; Zhao W; Yu SQ; Yuan H; Wang G; Sun H
    J Med Chem; 2017 Jul; 60(14):6077-6088. PubMed ID: 28650160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection.
    Liu S; Zhang Q; Shao X; Wang W; Zhang C; Jin Z
    Int Immunopharmacol; 2017 Sep; 50():87-94. PubMed ID: 28644966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection.
    Sung PS; Hong SH; Chung JH; Kim S; Park SH; Kim HM; Yoon SK; Shin EC
    Sci Rep; 2017 Jun; 7(1):3821. PubMed ID: 28630501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three-dimensional structure of the 3'X-tail of hepatitis C virus RNA in monomeric and dimeric states.
    Cantero-Camacho Á; Fan L; Wang YX; Gallego J
    RNA; 2017 Sep; 23(9):1465-1476. PubMed ID: 28630140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.
    Mücke VT; Mücke MM; Peiffer KH; Weiler N; Welzel TM; Sarrazin C; Zeuzem S; Berger A; Vermehren J
    Aliment Pharmacol Ther; 2017 Aug; 46(4):432-439. PubMed ID: 28627791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.